Publication:
Infantile hepatic hemangioendothelioma: Clinical presentation and treatment

dc.contributor.buuauthorSevinir, Betül
dc.contributor.buuauthorÖzkan, Tanju
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentPediatrik Onkoloji Ana Bilim Dalı
dc.contributor.departmentPediatrik Gastroenteroloji Ana Bilim Dalı
dc.contributor.orcid0000-0001-5740-9729
dc.contributor.researcheridAAH-1570-2021
dc.contributor.scopusid6603199915
dc.contributor.scopusid7004474005
dc.date.accessioned2022-10-24T11:39:14Z
dc.date.available2022-10-24T11:39:14Z
dc.date.issued2007-09
dc.description.abstractBachground/aims: Hepatic hemangioendotheliomas are rare tumors in childhood. We report our 10-years' experience in a tertiary health center. Methods: This retrospective analysis included eight patients with infantile hepatic hemangioendothelioma. Results: The median age at diagnosis was 24 days (age range: 1 to 70 days) and the female/male ratio was 5/3. The main symptoms were abdominal distention and respiratory distress. Cutaneous hemangiomas were present in four cases. Three infants had Kasabach-Merritt syndrome. Four cases had single hepatic tumors while the others had multiple. The tumor size ranged from 2 cm to 10 cm in diameter. These lesions were located equally in the right and left hepatic lobes, and three babies had bilobar involvement. Most of the multifocal hepatic tumors were associated with skin hemangiomas. Treatment options were assessed individually. Systemic prednisolone therapy (29 mg/kg/d) was commenced in six patients. Five patients responded to corticosteroids. One boy with Kasabach-Merritt syndrome did not respond to this therapy. Interferon-alpha (1 million units (MU)/m(2)/day) was started, and the daily dose of the drug was increased up to 10 MU/m(2), administered 3 times per week, until clinical improvement was achieved. The response was very good and we observed only constitutional adverse symptoms. Two cases were operated; one died from intraoperative bleeding. Other patients were alive and well for 11 to 66 months. Overall survival was 87% in our series. Conclusions: The treatment approaches depend on the centers experience. A multidisciplinary approach is required for the best treatment option.
dc.identifier.citationSevinir, B. ve Özkan, T. B. (2007). "Infantile hepatic hemangioendothelioma: Clinical presentation and treatment". Turkish Journal of Gastroenterology, 18(3), 182-187.
dc.identifier.endpage187
dc.identifier.issn1300-4948
dc.identifier.issn2148-5607
dc.identifier.issue3
dc.identifier.pubmed17891692
dc.identifier.scopus2-s2.0-43549120772
dc.identifier.startpage182
dc.identifier.urihttps://turkjgastroenterol.org/en/infantile-hepatic-hemangioendothelioma-clinical-presentation-and-treatment-1621485
dc.identifier.urihttp://hdl.handle.net/11452/29194
dc.identifier.volume18
dc.identifier.wos000254610300008
dc.indexed.scopusScopus
dc.indexed.trdizinTrDizin
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherAVES
dc.relation.journalTurkish Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHigh dose interferon-alpha treatment
dc.subjectKasabach-merritt syndrome
dc.subjectInfantile hepatic hemangioendothelioma
dc.subjectGastroenterology & hepatology
dc.subjectKasabach merritt phenomenon
dc.subjectTherapy
dc.subjectHemangiomas
dc.subjectManagement
dc.subjectInfancy
dc.subjectAlpha
dc.subject.emtreeBoy
dc.subject.emtreeAlpha interferon
dc.subject.emtreePrednisolone
dc.subject.emtreeAbdominal disease
dc.subject.emtreeAbdominal distention
dc.subject.emtreeArticle
dc.subject.emtreeBleeding
dc.subject.emtreeHemangioendothelioma
dc.subject.emtreeRetrospective study
dc.subject.emtreeClinical article
dc.subject.emtreeClinical feature
dc.subject.emtreeDrug dose increase
dc.subject.emtreeFemale
dc.subject.emtreeSkin hemangioma
dc.subject.emtreeInfantile hepatic hemangioendothelioma
dc.subject.emtreeHuman
dc.subject.emtreeHuman tissue
dc.subject.emtreeKasabach Merritt syndrome
dc.subject.emtreeLiver
dc.subject.emtreeLiver tumor
dc.subject.emtreeMale
dc.subject.emtreeNewborn
dc.subject.emtreeOverall survival
dc.subject.emtreeRespiratory distress
dc.subject.emtreeSymptom
dc.subject.emtreeTertiary health care
dc.subject.emtreeTumor volume
dc.subject.meshHumans
dc.subject.meshAbdomen
dc.subject.meshAlanine transaminase
dc.subject.meshAspartate aminotransferases
dc.subject.meshDilatation, pathologic
dc.subject.meshFemale
dc.subject.meshGlucocorticoids
dc.subject.meshHemangioendothelioma
dc.subject.meshHemangioma
dc.subject.meshHepatomegaly
dc.subject.meshImmunologic factors
dc.subject.meshRespiratory distress syndrome, newborn
dc.subject.meshPrednisolone
dc.subject.meshInfant
dc.subject.meshInfant, newborn
dc.subject.meshInterferon-alpha
dc.subject.meshLiver neoplasms
dc.subject.meshMale
dc.subject.meshNeoplasms, multiple primary
dc.subject.meshTurkey
dc.subject.meshRetrospective studies
dc.subject.meshSkin neoplasms
dc.subject.scopusHamartoma; Hemangioendothelioma; Hydatidiform Mole
dc.subject.wosGastroenterology & hepatology
dc.titleInfantile hepatic hemangioendothelioma: Clinical presentation and treatment
dc.title.alternativeİnfantil karaciğer hemanjioendotelyoması: Klinik ve tedavi
dc.typeArticle
dc.wos.quartileN/A
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Pediatrik Onkoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Pediatrik Gastroenteroloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sevinir_Özkan_2007.pdf
Size:
239.25 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: